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Abstract
Background: RET is the major gene associated to Hirschsprung disease (HSCR) with differential contributions of its
rare and common, coding and noncoding mutations to the multifactorial nature of this pathology. In the present
study, we have performed a comprehensive study of our HSCR series evaluating the involvement of both RET rare
variants (RVs) and common variants (CVs) in the context of the disease.
Methods: RET mutational screening was performed by dHPLC and direct sequencing for the identification of RVs.
In addition Taqman technology was applied for the genotyping of 3 RET CVs previously associated to HSCR,
including a variant lying in an enhancer domain within RET intron 1 (rs2435357). Statistical analyses were
performed using the SPSS v.17.0 to analyze the distribution of the variants.
Results: Our results confirm the strongest association to HSCR for the “enhancer” variant, and demonstrate a
significantly higher impact of it in male versus female patients. Integration of the RET RVs and CVs analysis showed
that in 91.66% of cases with both kinds of mutational events, the enhancer allele is in trans with the allele bearing
the RET RV.
Conclusions: A gender effect exists on both the transmission and distribution of rare coding and common HSCR
causing mutations. In addition, these RET CVs and RVs seem to act in a synergistic way leading to HSCR
phenotype.
Background
Hirschsprung disease (HSCR, OMIM #142623) is a con-
genital malformation of the hindgut produced by a dis-
ruption in the neural crest cells (NCC) migration during
embryonic development. This disorder results in an
absence of intramural ganglion cells in the submucosal
and myenteric plexuses producing a functional intestinal
obstruction. According to the aganglionic segment
length, patients could be classified as short-segment
HSCR (S-HSCR), when aganglionosis extend as far as
the rectosigmoid junction, and long-segment HSCR (L-
HSCR), when it extends beyond it. HSCR presents an
estimated incidence of 1/5000 live births with sex-
dependent penetrance and male predominance of 4:1
[1,2]. It most commonly presents sporadically, although
it can also be familial (up to 20% of the cases). The dis-
ease usually presents as isolated, though 30% of the
cases are associated with chromosomal abnormalities,
neurodevelopmental disorders and a variety of additional
isolated anomalies and syndromes [2].
HSCR has a complex genetic etiology with several
genes being described as associated with either isolated
or syndromic forms. These genes encode for receptors,
ligands (especially those participating in the RET and
EDNRB signaling transduction pathways), transcriptional
factors or other cell elements that are usually involved
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in the NCC development and migration that give rise to
the enteric nervous system (ENS). Nevertheless, the RET
proto-oncogene (OMIM +164761) is considered the
major disease causing gene in HSCR [2].
RET has been extensively studied in HSCR patients
and over 100 mutations have been identified along the
gene (see HGMD). However, mutations in the RET cod-
ing sequence (CDS) account for only up to 50% or 7-
20% of familial and sporadic cases, respectively [2]. The
involvement of RET in the pathogenesis of HSCR is
further supported by the existence of a specific haplo-
type, constituted by common RET polymorphisms,
which seems to be responsible for the majority of spora-
dic forms [3,4]. This HSCR-associated RET haplotype is
characterized by a common allele (c.73+9277T,
rs2435357) within a conserved enhancer-like sequence
in intron 1 (MCS+9.7) [3,5], making a 20-fold greater
contribution to risk than coding mutations do [3]. It has
been demonstrated a difference in ability of SOX10 to
bind to MCS+9.7 and transactivate RET depending on
the bearing allele at such specific locus [5]. Recently,
one SNP located closed to rs2435357 and in complete
linkage disequilibrium with it (c.73+9494A > C,
rs2506004) has been identified as a binding site for
NXF/ARNT2 and SIM2-ARNT2 that modifies RET
expression, demonstrating that more than one SNP can
influence gene expression and ultimately HSCR pheno-
type [6]. In this way, the combination of common var-
iants (CV), such as the so-called enhancer variants, and
rare variants (RV), such as RET CDS mutations, seems
to explain in part the complexity of HSCR.
In the present study, we have evaluated the implica-
tion of both RET CVs and RVs in our whole cohort of
282 Spanish patients. In order to elucidate the molecular
basis of the sex-dependent difference in HSCR we
sought to perform a case-control study to analyze the
distribution of the RET variants based in gender. In
addition, we have performed a segregation analysis in
patients for both RVs and CVs, with the aim to clarify
their contribution to HSCR phenotype.
Methods
Patients and Control Subjects
In the mutational screening we have included an
extension of our previously described cohort [7] incor-
porating a total of 176 new Spanish HSCR patients.
170 of these patients were sporadic cases, 6 were
familial belonging to 3 different families. Taking
together all the data, our cohort is constituted by a
total of 282 HSCR patients (253 sporadic and 29 famil-
ial cases belonging to 16 families). According to the
length of the aganglionic segment, the patients were
catalogued as S-HSCR (55,08%), L-HSCR (11,58%) and
Total Colonic Aganglionosis (TCA) (5,61%), while this
information was not available for 27,73% of HSCR
patients. Male:female ratios were 4:1 and 3:1 for short
and long forms (including the TCA patients), respec-
tively. 4,6% of our HSCR patients were syndromic
cases with Down syndrome (6 cases), Waardenburg
syndrome (2 cases), Ondine course (1 case), cardiopa-
thy (2 cases) or encephalopathy (2 cases). However due
to incomplete clinical data of part of our patients, our
percentage might be underestimated, taking into
account that the overall percentage reported for syn-
dromic HSCR patients is around 18% [2].
Genotyping analysis of RET CVs was performed exclu-
sively in the 253 sporadic cases of our cohort, since pre-
vious studies suggest that CVs have a minor effect in
familial cases, being those cases more probably asso-
ciated to CDS mutations in RET or other secondary
genes [2]. 103 of our sporadic cases had been already
evaluated in a previous study [8], thus we have geno-
typed the remaining 150 sporadic cases, as well as their
available parents. Trios necessary for the Transmission
Disequilibrium Test (TDT) analysis could be completed
in 134 of the 150 new families.
A total of 178 control individuals (129 males and 49
females) comprising unselected, unrelated, race, age, and
sex-matched individuals were included in this study. All
the controls were healthy voluntary donors, who came
to the Hospital for other reasons and did not present
any symptom suggestive of HSCR.
An informed consent was obtained from all the parti-
cipants for clinical and molecular genetic studies. The
study was approved by the Ethics Committee for clinical
research in the Hospital Universitario Virgen del Rocio
of Seville, and complies with the tenets of the declara-
tion of Helsinki.
PCR, dHPLC and Sequence analysis
We screened all the RET exons, including intron/exon
boundaries by PCR-dHPLC as previously described [7].
The exons of those patients with aberrant wave profiles
were subjected to sequence analysis as previously
reported [9]. When a novel RET variant was identified
in a proband, all the available family members were ana-
lyzed for the appropriate exon in order to perform the
corresponding segregation analysis.
Genotyping of RET SNPs and statistical analysis
We sought to analyze the distribution of three RET
SNPs (rs2435357 (c.73+9277T > C), rs2505532 (c.74-
1370C > T) and rs2565206 (c.74-126G > T)) in HSCR
patients to compare with that of the controls obtained
in our previous studies [4,8]. Large scale genotyping of
all these RET SNPs was performed using TaqMan-based
techniques for allelic discrimination (TaqMan® SNP
Genotyping Assay, Applied Biosystems, Foster City, CA)
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according to the manufacturer’s recommendations and
described elsewhere [10].
For each variant, Hardy-Weinberg equilibrium was veri-
fied in both the control and patients groups. Allelic and
genotypic frequencies of the 3 RET SNPs were calculated
and then compared between patients and controls. We
also compared transmitted versus non-transmitted alleles
from unaffected parents to affected offspring for each
locus. On the other hand, RET haplotypes were con-
structed as previously described [4,8], and their distribu-
tion was compared between patients and controls as well
as between transmitted and non-transmitted chromo-
somes in the context of the HSCR trios. Furthermore, alle-
lic, genotypic and haplotypic distributions were compared
between cases and controls in different subsets based in
gender (male patients versus male controls, and female
patients versus female controls). Despite the fact that the
group of male patients is higher that the group of females,
each subset of patients was compared to a group of sex-
matched controls similar in size. All the comparisons were
analysed using c2 test with Yate’s correction, considering
statistical significance at p < 0.05 and 2 degrees of freedom
(SPSS v.17.0 and R-software). For each variant we calcu-
lated the OR (95% CI) for the recessive, dominant and
additive models (unadjusted and adjusted for gender) [11],
and the generalized OR (GOR) (95% CI) [12].
Results
Identification of RET CDS mutations
In order to determine the mutational status of our whole
cohort of 282 HSCR patients, we developed a mutational
screening by dHPLC of the 176 cases that had not been
analyzed yet. RET mutational status of remaining 106
cases was available from a previous study [7].
We have detected 16 different germline mutations in a
total of 20 sporadic cases, all of them in heterozygosis
(Table 1, Figure 1). 13 of the 16 mutations are novel and
all of them, except for A156S, are predicted to be prob-
ably damaging variants using physical and comparative
considerations http://genetics.bwh.harvard.edu/pph/ and
http://blocks.fhcrc.org/sift/SIFT.html. Moreover, none of
them were detected in the control population tested. 10/
18 mutations are maternally inherited while inheritance
from paternal origin occurs with a similar frequency than
the de novo events (4/18 and 4/18 respectively). With this
new data, our complete cohort of 282 HSCR patients pre-
sents a RET mutational frequency of 18.75% in familial
cases (3 CDS mutations in 16 families screened) and
11.11% in non familial cases (29 CDS mutations in the
253 sporadic patients screened).
Genotyping of RET SNPs
We have analyzed allelic and genotypic distribution of 3
RET SNPs for the new 150 sporadic HSCR cases not
previously tested [4,8] and for 178 controls individuals.
Allelic distributions for rs2435357 and rs2505532
showed similar statistical differences in cases vs controls
than previously observed (c2 = 135.41 p < < 10-6 and c
= 96.45, p < < 10-6 respectively), [4,8]. No statistical dif-
ference was found for rs2565206, although a slight trend
towards significance was observed (c = 3.62, p =
0.0569263). However, when we performed this analysis,
including not only the new cases but the whole series of
sporadic patients, the difference in the distribution of
this variant in cases vs controls get statistical signifi-
cance (c2 = 6.74, p = 0.0094106). Haplotypic distribu-
tion also resulted statistically different when comparing
HSCR patients with controls (c2 = 159.62 p < < 10-6).
Moreover, TDT analysis performed for the 134 HSCR
trios showed a statistical difference when comparing
transmitted haplotypes versus non transmitted haplo-
types (c2 = 87.82 p < < 10-6).
On other hand, we have performed an additional sta-
tistical analysis comparing allelic, genotypic and haploty-
pic distribution in different subsets of patients and
controls classified by gender (male patients vs male con-
trols, and female patients vs female controls). Allelic dis-
tribution of rs2435357 and rs2505532 was clearly
different in males and females HSCR patients compared
with the corresponding control individuals, but present-
ing a considerably higher difference in male cases (23
orders of magnitude larger in males than in females,
Table 2, Figure 2, Additional File 1). Regarding the
rs2565206 variant, its distribution was found to be sig-
nificantly different in male cases versus male controls
whereas no difference was observed in female patients
compared with female controls. Similar results were
obtained for the analysis of the genotypic distribution.
Haplotypic distribution was also different for both sets,
although distribution was perceptibly more different in
males (males: c2 = 167.6938, p = 2.26*10-34 females: c =
49.17491, p = 2.04*10-9). TDT applied to haplotypes was
also performed in male and female subsets and resulted
in an unequal transmission as we expected (males: c =
114.5463, p = 4.47*10-23; females: c = 42.91487, p =
3.84*10-8).
Analysis of the relative position of RET CDS mutations
and the enhancer variant
Both the genotyping of RET CVs and mutational screen-
ing of RET RVs was completed for 253 sporadic HSCR
patients. Of them, 34 (13%) cases presented neither RET
RVs nor the enhancer variant, 192 (76%) harbored only
the enhancer variant in either heterozygosis or homozy-
gosis, 13 (5%) had exclusively a RET RV (CDS), and 14
(6%) presented with both disease allelic types. The fre-
quency distributions of these four mutational classes
classified according to the gender presents similar
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results. Examining the patients with both kinds of muta-
tional events, segregation analysis let us to observe that
91.66% of cases (11 of 12 patients) harbors the “enhan-
cer mutation” in trans with respect the allele bearing
the RET RV. The remaining patient was homozygous
for the enhancer variant.
Of the 34 HSCR patients with no RET CDS mutation
and no enhancer variation, 11 presented another kind of
mutational events related with HSCR: 1 chromosomal
translocation (t(10:22)), 6 chromosomal 21 triplication
and 4 mutations in other HSCR genes (EDNRB, GDNF,
and NTF3) [7,13,14].
Discussion
Previous genome-wide linkage/association studies have
identified several modifier genes in different genomic
regions, but RET is the only gene known to play a
major role in all forms of HSCR susceptibility and a
Table 1 RET germline mutations identified in our series of HSCR patients
Patient Exon/
Intron
Nucleotide
change
Amino acid
change
Parent origin of the
mutation
Gender Length of aganglionic
segment
Ref.
HSCR 193 2 c.287A > C p.Tyr96Ser Mother Female Not Available –
HSCR 133 3 c.466 G > T p.Ala156Ser De novo Female S-HSCR –
HSCR 166 5 c.937 C > T p.Arg313Trp Mother Male Not Available –
HSCR
V135
5 c.988insC p.R330PfsX353 Mother Male S-HSCR –
HSCR 223 5 c.1042 C > T p.Arg348Trp Mother Male Not Available –
HSCR 109 6 c.1118 C > T p.Ala373Val Father Female S-HSCR [7]
HSCR 217 6 c.1118 C > T p.Ala373Val Mother Male S-HSCR [7]
HSCR 220 6 c.1118 C > T p.Ala373Val Mother Male S-HSCR [7]
HSCR 99 7 c.1267G > A p.Gly423Arg Mother Female S-HSCR –
HSCR V67 7 c.1325T > C p. Leu442Pro Mother Male Not Available –
HSCR 187 8 c.1627 T > A p.Trp543Arg De novo Female S-HSCR –
HSCR 260 10 c.1859G > A p.Cys620Tyr Father Male L-HSCR –
HSCR V24 14 c.2459G > A p. Arg820His De novo Male Not Available –
HSCR 204 17 c.2858 C > T p.Pro953Leu Mother Male S-HSCR –
HSCR 278 18 c.2944 C > T p.Arg982Cys Not Available Male S-HSCR [19]
HSCR V22 18 c.2944 C > T p.Arg982Cys Father Male Not Available [19]
HSCR 15 18 c. 2975 C > T p.Pro992Leu De novo Male L-HSCR –
HSCR 151 19 c.3185 A > G p.Tyr1062Cys Mother Female S-HSCR [20]
HSCR 198 19 c.3185 A > G p.Tyr1062Cys Father Male Not Available [20]
HSCR 278 20 c*4delTCTTinsAAA NA Male S-HSCR –
Figure 1 Schematic representation of RET protein. Mutations identified in this study are indicated in the corresponding functional domain.
Novel and published mutations are presented in black and grey, respectively.
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quantitative study of its allelic spectrum should provide
clues on the role of both rare and common sequence
variants in the complex inheritance of HSCR, particu-
larly its relationships to factors that are correlated with
risk, such as gender.
After our RET CDS mutational screening, we have
found that our whole series of Spanish HSCR patients
presents a mutational frequency of 11.11% in sporadic
cases and 18.75% in familial ones, which is concordant
with previous studies that report values of up to 50% in
familial forms and 7-20% in sporadic cases [2].
Genotyping analysis of RET common SNPs shows
similar results to those previously described, confirming
thereby the prominent role of either the intronic enhan-
cer mutation (rs2435357, [3]) or the RET “risk haplo-
type” [4,8] in the pathogenesis of sporadic HSCR.
As previously commented, one of the major features
of HSCR, especially in the short-segment forms, is the
sex-dependent penetrance and male predominance of
4:1 [1]. Nevertheless the reason of this sex difference is
still unclear. It has been postulated that sex differences
could arise from mutations on the × chromosome, but
genome-wide mapping studies have failed to identify an
X-linked gene with a relevant impact per se in HSCR.
Previous studies have indeed demonstrated differences
in the transmission frequency of the “enhancer muta-
tion” (rs2435357) depending on the offspring gender or
parent gender [3,5]. For this reason, we sought to per-
form an additional case-control study to analyze the dis-
tribution of the RET variants based in gender. We found
a different allelic distribution between HSCR cases and
controls in both, males and females, for rs2435357 and
rs2505532. However and noteworthy, significant differ-
ences in HSCR versus controls in the male subset were
considerably increased with respect the female subset,
which is concordant with the sex-biased transmission of
the rs2435357 variant published by Emison et al. Never-
theless, no significant differences were found when com-
paring males vs females, in agreement with the similarity
in transmission frequency by gender after applying TDT
reported by Emison et al., 2010 [5]. The same phenom-
enon was observed for the haplotype analysis, which as
a whole is consistent with the greater incidence in males
than in females. However we cannot discard the possibi-
lity that the difference in the sample size of the corre-
sponding subsets might be interfering to some extent in
the results observed.
On the other hand, the association of rs2565206 to
HSCR has been found to be sex-dependent and
restricted to males. Probably, for this reason this SNP
presented association to HSCR only when we extended
our cohort, since we increased considerably the propor-
tion of male HSCR cases. It is relevant to note that this
specific variant has also been previously proposed to
have a role in the pathogenesis of sporadic medullary
thyroid cancer, since an over-representation of the T
allele was found in different studies reported [8,15,16].
Although the most accepted hypothesis to explain these
associations is the linkage with a still unidentified func-
tional locus within or nearby RET, it has been proposed
as well that this variant might slightly modulate per se
the expression of the RET proto-oncogene, given that a
new binding motif is created for NAFT transcription
factor in the presence of the T allele [8]. The restriction
Table 2 Allelic distribution frequency of the RET SNPs
Male female
RET variants Alleles HSCR (%) Controls (%) HSCR (%) Controls (%)
c.73+9277T > C T 250 (64.77) 52 (20.15) 37 (56.06) 21 (21.43)
rs2435357 C 136 (35.24) 206 (79.85) 29 (43.93) 77 (78.57)
c2 = 121.79 p = 2.55·10-28¬ c2 = 36.96 p = 0.0000117¬
c.74-1370C > T C 328 (84.97) 143 (55.43) 56 (84.85) 46 (46.94)
rs2505532 T 58 (15.03) 115 (44.57) 10 (15.15) 52 (53.06)
c2 = 67.22 p = 2.42·10-16¬ c2 = 22.52 p = 0.0000021¬
c.74-126G > T G 300 (77.72) 175 (67.83) 48 (72.72) 70 (71.42)
rs2565206 T 86 (22.28) 83 (32.17) 18 (27.27) 28 (28.57)
c2 = 7.31 p = 0.0068453¬ c2 = 0.00 p = 0.9965511
Figure 2 Allelic distribution frequency of RET enhancer variant
rs2435357 in Male and Female subset.
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to association of the G allele to the male subset of
HSCR patients could be therefore considered as another
hallmark of the complex nature of Hirschsprung disease.
After the evaluation of RVs and CVs in our HSCR ser-
ies, we have classified our cohort of patients according
to RET mutational status in 4 subsets (CDS mutation
only, enhancer mutation only, both or any of those
events) obtaining similar frequencies in these subsets
than Emison et al [5]. Nevertheless, taking a further step
in this study we performed a complete segregation ana-
lysis in patients with both RV and CV. 91.66% of cases
with both mutational events resulted to present the
enhancer variant in trans with regard to the CDS muta-
tion. It supports that the CVs may act as modifier alleles
of that bearing the RV, as speculated by Emison et al
[5]. In this way, we could be talking about a synergy
effect between two alleles, which is in agreement with
the additive/multiplicative model proposed for HSCR.
On the other hand, in our cohort, we have detected a 13%
of cases with no RET RVs or CVs. It has been previously
proposed that mutations in other HSCR genes could be
responsible for the HSCR phenotype in those patients, but
the analysis of other HSCR genes and chromosomal altera-
tions can only explain 31% of these cases. Alternatively,
RET deletions have been also proposed as a possible under-
lying molecular mechanism [5], although our MLPA analy-
sis revealed the absence of this kind of mutational event
affecting RET or other HSCR genes [17,18]. Nevertheless,
we cannot discard the presence of deletions in non-coding
regulatory regions of RET or other HSCR genes which may
lead to a loss-of-function of the protein.
Conclusions
In summary, from our whole results we could extract
several conclusions: (1) A gender effect exists on both
the transmission and distribution of rare coding and
common HSCR causing mutations (2) The variant
rs2565206 has been found to be associated to HSCR in
a sex-dependent manner, being such association
restricted to male patients (3) RET CVs and RVs seem
to act in a synergistic way leading to HSCR phenotype
(4) A portion of HSCR cases without RET CVs and RVs
might be explained by mutational events in another still
unidentified HSCR loci, and efforts should be made to
propose alternative methodological approaches that
could lead to the elucidation of their molecular causes.
Additional material
Additional File 1: Calculations of OR and GOR values. OR (95% CI)
and the generalized OR (GOR) (95% CI) were calculated for the recessive,
dominant and additive models for each variant (unadjusted and adjusted
for gender).
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